Gilead Sciences reported $30.5B of revenue over the trailing twelve months, +5.5% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $30.5B (to Q2 2026). Net income: −$3.24B, trailing twelve months to Q2 2026. Free cash flow: $12.9B, trailing twelve months to Q2 2026. Operating margin: −7.0%, trailing twelve months to Q2 2026.

GILDGilead Sciences

Healthcare

$151.17+36% 1Y

$151.17

$108.5052 weeks$153.91

GILD as reported

Gilead Sciences reported $30.5B of revenue over the trailing twelve months, +5.5% on the year before. 11 reported series are charted on this page, each one as filed.

$30.5B

Revenue, trailing twelve months · to Q2 2026 · +5.5% against the twelve months before

Net income: −$3.24B
Net income · −151% year on year · trailing twelve months to Q2 2026
Free cash flow: $12.9B
Free cash flow · +38% year on year · trailing twelve months to Q2 2026
Operating margin: −7.0%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for GILD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$30.5B	+5.5%	Q2 2026
Net income	−$3.24B	−151%	Q2 2026
EPS	−$2.67	−153%	Q2 2026
Gross margin	80%	n/a	Q2 2026
Operating margin	−7.0%	n/a	Q2 2026
Net margin	−9.7%	n/a	Q2 2026
ROE	22%	n/a	Q2 2026
ROA	9.5%	n/a	Q2 2026
ROIC	14%	n/a	Q2 2026
Free cash flow	$12.9B	+38%	Q2 2026
P/E	18.8	n/a	Q1 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.